A Phase 2 interventional study of NNZ-2591 in Phelan-McDermid Syndrome, sponsored by Neuren Pharmaceuticals Limited. Completed at 4 sites in United States. Open to participants aged 3 Years to 12 Years. Per ClinicalTrials.gov, last updated 2025-06-03.
Sponsored by Neuren Pharmaceuticals Limited · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Phelan-McDermid Syndrome.
The primary purpose of this study is to investigate the safety, tolerability and pharmacokinetics of treatment with NNZ-2591 oral solution in children and adolescents with Phelan-McDermid Syndrome. The secondary purpose is to investigate measures of efficacy. Subjects will receive treatment with NNZ-2591 oral solution (50 mg/mL) doses for a total of 13 weeks.
Neuren Pharmaceuticals Limited is the lead sponsor of 15 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
Drug: NNZ-2591
NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
Also known as: Cyclo-L-Glycyl-L-2-Allylproline
Safety and Tolerability
To examine the incidence, severity and frequency of adverse events (AEs), including serious adverse events (SAEs) during treatment with NNZ-2591.
Time frame: 13 weeks
Pharmacokinetic - Mean AUC24
Approximately nine sparse pharmacokinetic (PK) samples were collected from each participant under steady-state conditions. These samples were taken at pre-dose, 1-3 hours post-dose, and/or 4-7 hours post-dose during Weeks 2, 6, and 13. The individual pharmacokinetic parameters for NNZ-2591, including half-life (t1/2) and area under the curve over 24 hours (AUC24), were derived using subject-level concentration-time profiles from the study population model.
Time frame: Pre-dose, 1-3 h post-dose and/or 4-7 h post-dose at Weeks 2, 6 and 13.
Pharmacokinetic - t1/2
Approximately nine sparse pharmacokinetic (PK) samples were collected from each participant under steady-state conditions. These samples were taken at pre-dose, 1-3 hours post-dose, and/or 4-7 hours post-dose during Weeks 2, 6, and 13. The individual pharmacokinetic parameters for NNZ-2591, including half-life (t1/2) and area under the curve over 24 hours (AUC24), were derived using subject-level concentration-time profiles from the study population model.
Time frame: Pre-dose, 1-3 h post-dose and/or 4-7 h post-dose at Weeks 2, 6 and 13.
CGI-I
Phelan-McDermid Syndrome-specific Clinical Global Impression of Improvement Scale (CGI-I) - Overall Improvement Score on a 7 point Likert scale (1-7) where lower scores are better.
Time frame: CGI-I was assessed at Weeks 6, 13/EOT & 15. Overall improvement scores relate to Week 13/EOT visit.
CIC
Caregiver Impression of Improvement: Measured on a 7 point Likert scale (1-7) where lower scores are better.
Time frame: CIC was assessed at Week13/EOT
CGI-S
Phelan-McDermid syndrome-specific Clinical Global Impression Scale-Severity (CGI-S) -Change from baseline on Overall Score. Based on a 7 point Likert scale (1-7) where a lower score is better.
Time frame: Change in score assessed from baseline (visit 3, week 0) to visit 16 (week 13/EOT).
Top 3 Concerns
Caregiver Top 3 Concerns - Total Concerns Severity: Change from baseline. The range of scores was (0-30) for total concerns, with higher scores being worse
Time frame: Change from baseline (visit 3, week 0) to visit 13/EOT (week 16) in overall improvement score.
MB-CDI
MacArthur-Bates Communicative Development Inventory (MB-CDI) - change from baseline. Range of scores was (0-792) with higher scores being better.
Time frame: Change from baseline (visit 3, week 0) to visit 13/EOT (week 16).
ORCA
Observer-Reported Communication Ability (ORCA) - Change from baseline in Total Score. Range of Scores was (25.8-83.8) with higher scores being better
Time frame: Change from baseline (visit 3, week 0) to visit 13/EOT (week 16) in Total Score.
ABC-2
Aberrant Behavior Checklist-2 (ABC-2) - Total score: Change from baseline. Range of scores was (0-174) with higher scores being worse
Time frame: Change from baseline (visit 3, week 0) to visit 13/EOT (week 16) in total score.
CSHQ
Child Sleep Habits Questionnaire (CSHQ) - Change from baseline in Total Score. Range of scores was (33-99) with higher scores being worse.
Time frame: Change from baseline (visit 3, week 0) to visit 13/EOT (week 16) in total score.
GIHQ
Gastrointestinal Health Questionnaire (GIHQ) - Total Frequency Score: Change from Baseline. Range of scores was (0-212) with higher scores being worse.
Time frame: Change from baseline (visit 3, week 0) to visit 13/EOT (week 16) in total frequency score.
VABS-3
Vineland Adaptive Behavior Scales-3, Change from baseline in Composite Standard Score. Range of scores was (20-140) with higher scores being better.
Time frame: Change from baseline (visit 3, week 0) to visit 13/EOT (week 16) in composite standard score.
QL-Disability
Quality of Life Inventory-Disability (QL-Disability) Overall Score - change from baseline. Range of scores was (0-100) with higher scores being better.
Time frame: Change from baseline (visit 3, week 0) to visit 13/EOT (week 16) in overall score score.
ICND
Impact of Childhood Neurological Disability (ICND) - Change from baseline in overall quality of life rating. Range of (1- 6) for quality of life rating, with higher scores indicating greater impact.
Time frame: Change from baseline (visit 3, week 0) to visit 13/EOT (week 16) in overall quality of life rating score.
PMS-DSRS
PMS Clinician Domain Specific Rating Scale - Change from baseline in overall severity score. Range of Scores Was (0-20) With Higher Scores Being Worse.
Time frame: Change from baseline (visit 3, week 0) to visit 13/EOT (week 16) in overall severity score.
Behavior Problems Inventory - Short Form
Total Frequency Score - Change from Baseline. Range of scores was (0-4) for each of 30 behaviors, total range (0-120), with lower scores being better.
Time frame: Change from baseline (visit 3, week 0) to visit 13/EOT (week 16) in total frequency score.
Participants were recruited based on physician referral at 4 academic medical centers between August 2022 and June 2023. The first participant entered screening on 08 August 2022, and the last participant entered screening on 22 June 2023. Of 23 consented participants, 18 met eligibility criteria and were enrolled into the study. Enrolled participants received NNZ2591 12 mg/kg by liquid oral dose twice daily
| Milestone | NNZ-2591 |
|---|---|
| Started | 23 |
| Completed | 18 |
| Not completed | 5 |
| Withdrew: Failed screening | 5 |
| Milestone | NNZ-2591 |
|---|---|
| Started | 18 |
| Completed | 15 |
| Not completed | 3 |
| Withdrew: Adverse event | 3 |
To examine the incidence, severity and frequency of adverse events (AEs), including serious adverse events (SAEs) during treatment with NNZ-2591.
| Participants | NNZ-2591 |
|---|---|
| Participants with any AE | 17 |
| Participants with TEAE | 17 |
| Participants with Serious TEAE | 1 |
| Participants who discontinued due to TEAE | 3 |
| Participants with mild TEAE | 11 |
| Participants with moderate TEAE | 5 |
| Participants with severe TEAE | 1 |
Approximately nine sparse pharmacokinetic (PK) samples were collected from each participant under steady-state conditions. These samples were taken at pre-dose, 1-3 hours post-dose, and/or 4-7 hours post-dose during Weeks 2, 6, and 13. The individual pharmacokinetic parameters for NNZ-2591, including half-life (t1/2) and area under the curve over 24 hours (AUC24), were derived using subject-level concentration-time profiles from the study population model.
| µg.h/mL | PK Population |
|---|---|
| Pharmacokinetic - Mean AUC24 | 411 ± 116 |
Approximately nine sparse pharmacokinetic (PK) samples were collected from each participant under steady-state conditions. These samples were taken at pre-dose, 1-3 hours post-dose, and/or 4-7 hours post-dose during Weeks 2, 6, and 13. The individual pharmacokinetic parameters for NNZ-2591, including half-life (t1/2) and area under the curve over 24 hours (AUC24), were derived using subject-level concentration-time profiles from the study population model.
| hours | PK Population |
|---|---|
| Pharmacokinetic - t1/2 | 8.02 ± 2.33 |
Phelan-McDermid Syndrome-specific Clinical Global Impression of Improvement Scale (CGI-I) - Overall Improvement Score on a 7 point Likert scale (1-7) where lower scores are better.
| score on a scale | NNZ-2591 |
|---|---|
| CGI-I | 2.4 ± 0.86 |
Caregiver Impression of Improvement: Measured on a 7 point Likert scale (1-7) where lower scores are better.
| score on a scale | NNZ-2591 |
|---|---|
| CIC | 2.7 ± 1.02 |
Phelan-McDermid syndrome-specific Clinical Global Impression Scale-Severity (CGI-S) -Change from baseline on Overall Score. Based on a 7 point Likert scale (1-7) where a lower score is better.
| score on a scale | NNZ-2591 |
|---|---|
| CGI-S | -0.4 ± 0.5 |
Caregiver Top 3 Concerns - Total Concerns Severity: Change from baseline. The range of scores was (0-30) for total concerns, with higher scores being worse
| score on a scale | NNZ-2591 |
|---|---|
| Top 3 Concerns | -5.9 ± 5.86 |
MacArthur-Bates Communicative Development Inventory (MB-CDI) - change from baseline. Range of scores was (0-792) with higher scores being better.
| score on a scale | NNZ-2591 |
|---|---|
| MB-CDI | 12.3 ± 35.19 |
Observer-Reported Communication Ability (ORCA) - Change from baseline in Total Score. Range of Scores was (25.8-83.8) with higher scores being better
| score on a scale | NNZ-2591 |
|---|---|
| ORCA | 1.9 ± 4.22 |
Aberrant Behavior Checklist-2 (ABC-2) - Total score: Change from baseline. Range of scores was (0-174) with higher scores being worse
| score on a scale | NNZ-2591 |
|---|---|
| ABC-2 | -17.2 ± 19.65 |
Child Sleep Habits Questionnaire (CSHQ) - Change from baseline in Total Score. Range of scores was (33-99) with higher scores being worse.
| score on a scale | NNZ-2591 |
|---|---|
| CSHQ | -3.6 ± 5.68 |
Gastrointestinal Health Questionnaire (GIHQ) - Total Frequency Score: Change from Baseline. Range of scores was (0-212) with higher scores being worse.
| score on a scale | NNZ-2591 |
|---|---|
| GIHQ | -9.6 ± 10.8 |
Vineland Adaptive Behavior Scales-3, Change from baseline in Composite Standard Score. Range of scores was (20-140) with higher scores being better.
| score on a scale | NNZ-2591 |
|---|---|
| VABS-3 | 2.8 ± 7.82 |
Quality of Life Inventory-Disability (QL-Disability) Overall Score - change from baseline. Range of scores was (0-100) with higher scores being better.
| score on a scale | NNZ-2591 |
|---|---|
| QL-Disability | 6.1 ± 8.91 |
Impact of Childhood Neurological Disability (ICND) - Change from baseline in overall quality of life rating. Range of (1- 6) for quality of life rating, with higher scores indicating greater impact.
| score on a scale | NNZ-2591 |
|---|---|
| ICND | 0.3 ± 0.69 |
PMS Clinician Domain Specific Rating Scale - Change from baseline in overall severity score. Range of Scores Was (0-20) With Higher Scores Being Worse.
| score on a scale | NNZ-2591 |
|---|---|
| PMS-DSRS | -0.9 ± 1.69 |
Total Frequency Score - Change from Baseline. Range of scores was (0-4) for each of 30 behaviors, total range (0-120), with lower scores being better.
| score on a scale | NNZ-2591 |
|---|---|
| Behavior Problems Inventory - Short Form | -5.1 ± 9.41 |
Collected over 15 weeks for each participant starting on date of first dose. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NNZ-2591 | 0/18 (0%) | 1/18 (5.6%) | 17/18 (94.4%) |
| Event | NNZ-2591 |
|---|---|
| GastroenteritisGastrointestinal disorders | 1/18 |
| Event | NNZ-2591 |
|---|---|
| Psychomotor HyperactivityNervous system disorders | 4/18 |
| PyrexiaGeneral disorders | 3/18 |
| Covid 19Infections and infestations | 3/18 |
| Decreased appetiteMetabolism and nutrition disorders | 3/18 |
| SomnolenceNervous system disorders | 3/18 |
| ConstipationGastrointestinal disorders | 2/18 |
| DiarrheaGastrointestinal disorders | 2/18 |
| NauseaGastrointestinal disorders | 2/18 |
| VomitingGastrointestinal disorders | 2/18 |
| FatigueGeneral disorders | 2/18 |
Intention to treat
| Age, Continuous(years) | NNZ-2591 |
|---|---|
| Mean | 8.6 ± 2.7 |
| Sex: Female, Male(Participants) | NNZ-2591 |
|---|---|
| Female | 6 |
| Male | 12 |
| Race/Ethnicity, Customized(Participants) | NNZ-2591 |
|---|---|
| Race : White | 16 |
| Race : Black or African American | 1 |
| Race : Asian | 0 |
| Race : Native Hawaiian or other Pacific Islander | 0 |
| Race : American Indian or Alaska Native | 0 |
| Race : Multi Racial | 1 |
| Race : Other | 0 |
| Ethnicity : Hispanic or Latino | 3 |
| Ethnicity : Not Hispanic or Latino | 15 |
| Height (cm)(cm) | NNZ-2591 |
|---|---|
| Mean | 130.6 ± 15.15 |
| Weight (kg)(kg) | NNZ-2591 |
|---|---|
| Mean | 30.4 ± 10.75 |
| BMI (kg/m^2)(kg/m^2) | NNZ-2591 |
|---|---|
| Mean | 17.4 ± 3.48 |
| PMS Genotype(Participants) | NNZ-2591 |
|---|---|
| Terminal Deletion - Class I | 7 |
| Terminal Deletion - Class II | 3 |
| Ring 22 | 0 |
| Unbalanced Translocation | 0 |
| Interstitial Deletion | 1 |
| SHANK 3 variant/mutation | 6 |
| Other | 1 |
| History of regression(Participants) | NNZ-2591 |
|---|---|
| Yes | 11 |
| No | 7 |
7 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2022 to primary completion in Nov 2023, 14 months.
Results were first posted in May 2025, 1 year 6 months after primary completion. A results delay was requested in Oct 2024.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ercanetide
Telomeric 22q13 Monosomy Syndrome
Neuren Pharmaceuticals Limited